Cover Image
市場調查報告書

酪胺酸蛋白激酶受體UFO:開發中產品分析

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 367823
出版日期 內容資訊 英文 132 Pages
訂單完成後即時交付
價格
Back to Top
酪胺酸蛋白激酶受體UFO:開發中產品分析 Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Pipeline Review, H1 2018
出版日期: 2018年05月16日 內容資訊: 英文 132 Pages
簡介

本報告提供以酪胺酸蛋白激酶受體UFO為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

酪胺酸蛋白激酶受體UFO 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Astellas Pharma Inc.
  • BerGenBio AS
  • Betta Pharmaceuticals Co. Ltd.
  • 中外製藥
  • Exelixis, Inc.
  • HEC Pharm Co., Ltd.
  • Ignyta, Inc.
  • Les Laboratoires Servier SAS
  • Mirati Therapeutics Inc.
  • NeoPharm Co., Ltd.
  • Oribase Pharma
  • SignalChem Lifesciences Corp
  • Tolero Pharmaceuticals, Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1455TDB

Summary:

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Tyrosine-protein kinase receptor UFO is an enzyme encoded by the AXL gene. It plays a role in various processes such as endothelial cell survival during acidification by preventing apoptosis, optimal cytokine signaling during human natural killer cell development, hepatic regeneration, gonadotropin-releasing hormone neuron survival and migration, platelet activation, or regulation of thrombotic responses. It plays also an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response.

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) pipeline Target constitutes close to 27 molecules. Out of which approximately 26 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 4, 5, 1, 12 and 2 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular and Respiratory which include indications Non-Small Cell Lung Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Solid Tumor, Breast Cancer, Ovarian Cancer, Refractory Acute Myeloid Leukemia, Pancreatic Cancer, Relapsed Acute Myeloid Leukemia, Bladder Cancer, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Gastric Cancer, Hepatocellular Carcinoma, Lung Adenocarcinoma, Melanoma, Metastatic Colorectal Cancer, Metastatic Renal Cell Carcinoma, Renal Cell Carcinoma, Soft Tissue Sarcoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Bile Duct Cancer (Cholangiocarcinoma), Bone Metastasis, Carcinoid Tumor, Colorectal Cancer, Endometrial Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Ewing Sarcoma, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor (GIST), Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Idiopathic Pulmonary Fibrosis, Kidney Cancer (Renal Cell Cancer), Liposarcoma, Liver Cancer, Lung Cancer, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Brain Tumor, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Prostate Cancer, Myelodysplastic Syndrome, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Neuroendocrine Tumors, Non-Rhabdomyosarcoma, Ocular Melanoma, Osteosarcoma, Pancreatic Ductal Adenocarcinoma, Peritoneal Cancer, Pheochromocytoma, Recurrent Glioblastoma Multiforme (GBM), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rhabdomyosarcoma, Thrombosis, Thyroid Cancer, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Ureter Cancer, Urethral Cancer, Uterine Cancer and Wilms' Tumor (Nephroblastoma).

The latest report Tyrosine Protein Kinase Receptor UFO - Pipeline Review, H1 2018, outlays comprehensive information on the Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1)
  • The report reviews Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Overview
    • Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Companies Involved in Therapeutics Development
    • ADC Therapeutics SA
    • Astellas Pharma Inc
    • BerGenBio ASA
    • Betta Pharmaceuticals Co Ltd
    • Celldex Therapeutics Inc
    • Daiichi Sankyo Co Ltd
    • Exelixis Inc
    • F1 Oncology Inc
    • Ignyta Inc
    • Incyte Corp
    • Les Laboratoires Servier SAS
    • Mirati Therapeutics Inc
    • Ono Pharmaceutical Co Ltd
    • Oribase Pharma
    • Qurient Co Ltd
    • Rigel Pharmaceuticals Inc
    • SignalChem Lifesciences Corp
    • Takeda Pharmaceutical Co Ltd
    • Tolero Pharmaceuticals Inc
  • Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Drug Profiles
    • ADCT-601 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antibodies to Inhibit AXL, MERTK and TYRO3 for Oncology, Inflammation, Autoimmune Diseases and Infectious Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bemcentinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BGB-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BGB-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BGB-149 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BGB-601 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BPI-9016 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cabozantinib s-malate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCT-30138 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CT-053 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CT-413 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DS-1205 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Fusion Protein to Inhibit Axl Tyrosine kinase for Non-Small Cell Lung Cancer and Thrombosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • gilteritinib fumarate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HOPE-777 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INCB-81776 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ONO-7475 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ORY-012 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Q-701 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-916562 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RXDX-106 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-49076 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sitravatinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SLC-0211 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit AXL for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TP-0903 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Dormant Products
  • Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Discontinued Products
  • Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Product Development Milestones
    • Featured News & Press Releases
      • Apr 26, 2018: Cabozantinib to Be Featured in 15 Presentations at ASCO 2018 Annual Meeting
      • Apr 23, 2018: Astellas Submits New Drug Applications for Approval of Gilteritinib for the Treatment of FLT3mut+ Relapsed or Refractory Acute Myeloid Leukemia
      • Apr 18, 2018: BerGenBio: Promising data highlighting selective AXL inhibitor bemcentinib's potential to improve efficacy of checkpoint inhibitors presented at AACR
      • Apr 13, 2018: Promising pre-clinical data supporting BerGenBios pipeline to be published and presented at upcoming leading conferences
      • Apr 11, 2018: ADC Therapeutics to Present New Investigational Antibody-Drug Conjugate ADCT-601 at the American Association for Cancer Research (AACR) Annual Meeting
      • Apr 10, 2018: BerGenBio Completes Recruitment Into First Stage of Phase II NSCLC Trial With Selective AXL Inhibitor Bemcentinib Combined With KEYTRUDA
      • Mar 28, 2018: Ipsen Announces EMA Validation of Filing of a New Application for Additional Indication for Cabometyx, for patients with previously treated advanced Hepatocellular Carcinoma (HCC)
      • Mar 23, 2018: Exelixis Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX (cabozantinib) for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma
      • Mar 22, 2018: BerGenBio to present overview of phase II clinical trial portfolio combining bemcentinib with KEYTRUDA at 3rd Annual Immuno-Oncology Summit Europe
      • Mar 22, 2018: Astellas Receives Orphan Drug Designation from the Japanese MHLW for Gilteritinib
      • Mar 15, 2018: Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX (Cabozantinib) for Previously Treated Advanced Hepatocellular Carcinoma
      • Mar 15, 2018: BerGenBio: Promising data highlighting bemcentinib's potential to improve efficacy of checkpoint inhibitors to be presented at AACR Annual Meeting
      • Feb 19, 2018: BerGenBio Completes Recruitment Into First Stage of Phase II Breast Cancer Trial With Selective AXL Inhibitor Bemcentinib Combined With KEYTRUDA
      • Feb 15, 2018: Ipsen's rare medullary thyroid cancer treatment Cometriq (cabozantinib), gets nod from NICE
      • Feb 13, 2018: Cabozantinib shows significant activity in the first line for differentiated thyroid cancer
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indications, H1 2018
  • Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
  • Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018
  • Number of Products under Development by Indications, H1 2018 (Contd..3), H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Companies, H1 2018 (Contd..1)
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..3), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..4), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..5), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..6), H1 2018
  • Number of Products under Investigation by Universities/Institutes, H1 2018
  • Products under Investigation by Universities/Institutes, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by ADC Therapeutics SA, H1 2018
  • Pipeline by Astellas Pharma Inc, H1 2018
  • Pipeline by BerGenBio ASA, H1 2018
  • Pipeline by Betta Pharmaceuticals Co Ltd, H1 2018
  • Pipeline by Celldex Therapeutics Inc, H1 2018
  • Pipeline by Daiichi Sankyo Co Ltd, H1 2018
  • Pipeline by Exelixis Inc, H1 2018
  • Pipeline by F1 Oncology Inc, H1 2018
  • Pipeline by Ignyta Inc, H1 2018
  • Pipeline by Incyte Corp, H1 2018
  • Pipeline by Les Laboratoires Servier SAS, H1 2018
  • Pipeline by Mirati Therapeutics Inc, H1 2018
  • Pipeline by Ono Pharmaceutical Co Ltd, H1 2018
  • Pipeline by Oribase Pharma, H1 2018
  • Pipeline by Qurient Co Ltd, H1 2018
  • Pipeline by Rigel Pharmaceuticals Inc, H1 2018
  • Pipeline by SignalChem Lifesciences Corp, H1 2018
  • Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
  • Pipeline by Tolero Pharmaceuticals Inc, H1 2018
  • Dormant Products, H1 2018
  • Dormant Products, H1 2018 (Contd..1), H1 2018
  • Dormant Products, H1 2018 (Contd..2), H1 2018
  • Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Top 10 Indications, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top